AstraZeneca has revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
“We are very excited to be able to reveal the plans for our new site in Cambridge today. Our aim is to create an open, welcoming and vibrant centre that will inspire our teams and partners to push the boundaries of scientific innovation,” said Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development at AstraZeneca.
The new facility will be located on the Cambridge Biomedical Campus (CBC). The plans include designs for the Global Centre, an R&D Enabling Building and an Energy Centre. The new site will bring together AstraZeneca’s small molecule and biologics research and development activity. The CBC will be the new UK home for biologics research and protein engineering carried out by MedImmune, AstraZeneca’s biologics arm.
“With our combined AstraZeneca and MedImmune portfolios we are already uniquely positioned to explore the promise of combination therapies in transforming the way patients are treated,” said Dr. Bahija Jallal, Executive Vice President, MedImmune. “Our new Global Research Centre in Cambridge will see AstraZeneca and MedImmune scientists working side by side to advance science in our core therapeutic areas. This will support and strengthen our focus on combining the expertise across our business to develop new ways to treat patients and tackle the significant unmet need that exists in areas such as oncology.”
AstraZeneca expects to begin the build of the new site in early 2015.